story of the week
Biomarker Analyses in Patients With Metastatic Triple-Negative Breast Cancer Treated With Sacituzumab Govitecan vs Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer
Ann. Oncol 2021 Jun 08;[EPub Ahead of Print], A Bardia, SM Tolaney, K Punie, D Loirat, M Oliveira, K Kalinsky, A Zelnak, P Aftimos, F Dalenc, S Sardesai, E Hamilton, P Sharma, S Recalde, EC Gil, T Traina, J O'Shaughnessy, J Cortes, M Tsai, L Vahdat, V Diéras, LA Carey, HS Rugo, DM Goldenberg, Q Hong, M Olivo, LM Itri, SA HurvitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.